MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

Cell Reports

Volumn 13, Issue 12, 2015, Pages 2715-2727

  Benito, Juliana M ^a   Godfrey, Laura ^b   Kojima, Kensuke ^c   Hogdal, Leah ^d   Wunderlich, Mark ^e   Geng, Huimin ^f   Marzo, Isabel ^g   Harutyunyan, Karine G ^a   Golfman, Leonard ^a   North, Phillip ^b   Kerry, Jon ^b   Ballabio, Erica ^b   Chonghaile, Triona Ní ^h   Gonzalo, Oscar ^g   Qiu, Yihua ^a   Jeremias, Irmela ⁱ   Debose, LaKiesha ^a   O'Brien, Eric ^e   Ma, Helen ^a   Zhou, Ping ^a   Jacamo, Rodrigo ^a   Park, Eugene ^f   Coombes, Kevin R ^a   Zhang, Nianxiang ^a   Thomas, Deborah A ^a   O'Brien, Susan ^a   Kantarjian, Hagop M ^a   Leverson, Joel D ^j   Kornblau, Steven M ^a   Andreeff, Michael ^a   Müschen, Markus ^f   Zweidler McKay, Patrick A ^a   Mulloy, James C ^e   Letai, Anthony ^d   Milne, Thomas A ^b   Konopleva, Marina ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SAGA UNIVERSITY   (Japan)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF ZARAGOZA   (Spain)

^h ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

ⁱ INSTITUTE OF EPIDEMIOLOGY   (Germany)

^j ABBVIE INC   (United States)

more..

Author keywords

apoptosis pathways; bcl 2 family members; DOT1L; H3K79 methylation; leukemias; MLL AF4

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; PROTEIN BCL 2; VENETOCLAX; VINCRISTINE; FUSED HETEROCYCLIC RINGS; HISTONE LYSINE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; MLL PROTEIN, MOUSE; SULFONAMIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCL 2 GENE; CHILD; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; GENE ACTIVATION; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; METHYLATION; NONOBESE DIABETIC MOUSE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO ONCOGENE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; GENES, BCL-2; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; METHYLATION; MICE; MICE, INBRED NOD; MICE, SCID; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84975504780     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.12.003     Document Type: Article

References (45)

1. Alford, S.E., Kothari, A., Loeff, F.C., Eichhorn, J.M., Sakurikar, N., Goselink, H.M., Saylors, R.L., Jedema, I., Falkenburg, J.H., Chambers, T.C., BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 75 (2015), 1366–1375.
2. Andersson, A.K., Ma, J., Wang, J., Chen, X., Gedman, A.L., Dang, J., Nakitandwe, J., Holmfeldt, L., Parker, M., Easton, J., et al., St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 47 (2015), 330–337.
3. Beldjord, K., Chevret, S., Asnafi, V., Huguet, F., Boulland, M.L., Leguay, T., Thomas, X., Cayuela, J.M., Grardel, N., Chalandon, Y., et al., Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 123 (2014), 3739–3749.
4. Biswas, D., Milne, T.A., Basrur, V., Kim, J., Elenitoba-Johnson, K.S., Allis, C.D., Roeder, R.G., Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc. Natl. Acad. Sci. USA 108 (2011), 15751–15756.
5. Bursen, A., Schwabe, K., Rüster, B., Henschler, R., Ruthardt, M., Dingermann, T., Marschalek, R., The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 115 (2010), 3570–3579.
6. Certo, M., Del Gaizo Moore, V., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S.A., Letai, A., Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006), 351–365.
7. Chen, J., Jin, S., Abraham, V., Huang, X., Liu, B., Mitten, M.J., Nimmer, P., Lin, X., Smith, M., Shen, Y., et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol. Cancer Ther. 10 (2011), 2340–2349.
8. Chen, C.W., Koche, R.P., Sinha, A.U., Deshpande, A.J., Zhu, N., Eng, R., Doench, J.G., Xu, H., Chu, S.H., Qi, J., et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 21 (2015), 335–343.
9. Chonghaile, T.N., Roderick, J.E., Glenfield, C., Ryan, J., Sallan, S.E., Silverman, L.B., Loh, M.L., Hunger, S.P., Wood, B., DeAngelo, D.J., et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 4 (2014), 1074–1087.
10. Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.I., Robson, S.C., Chung, C.W., Hopf, C., Savitski, M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478 (2011), 529–533.
11. Del Gaizo Moore, V., Schlis, K.D., Sallan, S.E., Armstrong, S.A., Letai, A., BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111 (2008), 2300–2309.
12. Dreyer, Z.E., Hilden, J.M., Jones, T.L., Devidas, M., Winick, N.J., Willman, C.L., Harvey, R.C., Chen, I.M., Behm, F.G., Pullen, J., et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (cohort 3). Pediatr. Blood Cancer 62 (2015), 419–426.
13. Duy, C., Hurtz, C., Shojaee, S., Cerchietti, L., Geng, H., Swaminathan, S., Klemm, L., Kweon, S.M., Nahar, R., Braig, M., et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 473 (2011), 384–388.
14. Guenther, M.G., Lawton, L.N., Rozovskaia, T., Frampton, G.M., Levine, S.S., Volkert, T.L., Croce, C.M., Nakamura, T., Canaani, E., Young, R.A., Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 22 (2008), 3403–3408.
15. High, L.M., Szymanska, B., Wilczynska-Kalak, U., Barber, N., O'Brien, R., Khaw, S.L., Vikstrom, I.B., Roberts, A.W., Lock, R.B., The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol. Pharmacol. 77 (2010), 483–494.
16. Kang, M.H., Kang, Y.H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M.A., Harned, T.M., Lock, R.B., Reynolds, C.P., Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110 (2007), 2057–2066.
17. Kornblau, S.M., Qiu, Y.H., Zhang, N., Singh, N., Faderl, S., Ferrajoli, A., York, H., Qutub, A.A., Coombes, K.R., Watson, D.K., Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood 118 (2011), 5604–5612.
18. Krivtsov, A.V., Feng, Z., Lemieux, M.E., Faber, J., Vempati, S., Sinha, A.U., Xia, X., Jesneck, J., Bracken, A.P., Silverman, L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14 (2008), 355–368.
19. Kuntimaddi, A., Achille, N.J., Thorpe, J., Lokken, A.A., Singh, R., Hemenway, C.S., Adli, M., Zeleznik-Le, N.J., Bushweller, J.H., Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. Cell Rep. 11 (2015), 808–820.
20. Leach, B.I., Kuntimaddi, A., Schmidt, C.R., Cierpicki, T., Johnson, S.A., Bushweller, J.H., Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure 21 (2013), 176–183.
21. Leverson, J.D., Phillips, D.C., Mitten, M.J., Boghaert, E.R., Diaz, D., Tahir, S.K., Belmont, L.D., Nimmer, P., Xiao, Y., Ma, X.M., et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med., 7, 2015, 279ra40.
22. Lin, C., Smith, E.R., Takahashi, H., Lai, K.C., Martin-Brown, S., Florens, L., Washburn, M.P., Conaway, J.W., Conaway, R.C., Shilatifard, A., AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 37 (2010), 429–437.
23. Maethner, E., Garcia-Cuellar, M.P., Breitinger, C., Takacova, S., Divoky, V., Hess, J.L., Slany, R.K., MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. Cell Rep. 3 (2013), 1553–1566.
24. Menges, C.W., Altomare, D.A., Testa, J.R., FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell Cycle 8 (2009), 2528–2534.
25. Milne, T.A., Zhao, K., Hess, J.L., Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. Methods Mol. Biol. 538 (2009), 409–423.
26. Mohan, M., Herz, H.M., Takahashi, Y.H., Lin, C., Lai, K.C., Zhang, Y., Washburn, M.P., Florens, L., Shilatifard, A., Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 24 (2010), 574–589.
27. Molica, S., Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology. Expert Rev. Hematol. 8 (2015), 277–281.
28. Mueller, D., Bach, C., Zeisig, D., Garcia-Cuellar, M.P., Monroe, S., Sreekumar, A., Zhou, R., Nesvizhskii, A., Chinnaiyan, A., Hess, J.L., Slany, R.K., A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110 (2007), 4445–4454.
29. Pan, R., Hogdal, L.J., Benito, J.M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D.J., Debose, L., Mu, H., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4 (2014), 362–375.
30. Pieters, R., Schrappe, M., De Lorenzo, P., Hann, I., De Rossi, G., Felice, M., Hovi, L., LeBlanc, T., Szczepanski, T., Ferster, A., et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370 (2007), 240–250.
31. Robinson, B.W., Behling, K.C., Gupta, M., Zhang, A.Y., Moore, J.S., Bantly, A.D., Willman, C.L., Carroll, A.J., Adamson, P.C., Barrett, J.S., Felix, C.A., Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br. J. Haematol. 141 (2008), 827–839.
32. Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, S.L., Catron, N.D., Chen, J., Dayton, B.D., Ding, H., Enschede, S.H., Fairbrother, W.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19 (2013), 202–208.
33. Suryani, S., Carol, H., Chonghaile, T.N., Frismantas, V., Sarmah, C., High, L., Bornhauser, B., Cowley, M.J., Szymanska, B., Evans, K., et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 20 (2014), 4520–4531.
34. Szymanska, B., Wilczynska-Kalak, U., Kang, M.H., Liem, N.L., Carol, H., Boehm, I., Groepper, D., Reynolds, C.P., Stewart, C.F., Lock, R.B., Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS ONE, 7, 2012, e33894.
35. Tan, N., Malek, M., Zha, J., Yue, P., Kassees, R., Berry, L., Fairbrother, W.J., Sampath, D., Belmont, L.D., Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin. Cancer Res. 17 (2011), 1394–1404.
36. Terziyska, N., Castro Alves, C., Groiss, V., Schneider, K., Farkasova, K., Ogris, M., Wagner, E., Ehrhardt, H., Brentjens, R.J., zur Stadt, U., et al. In vivo imaging enables high resolution preclinical trials on patients’ leukemia cells growing in mice. PLoS ONE, 7, 2012, e52798.
37. Thomas, M., Gessner, A., Vornlocher, H.P., Hadwiger, P., Greil, J., Heidenreich, O., Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 106 (2005), 3559–3566.
38. Urtishak, K.A., Edwards, A.Y., Wang, L.S., Hudome, A., Robinson, B.W., Barrett, J.S., Cao, K., Cory, L., Moore, J.S., Bantly, A.D., et al. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood 121 (2013), 2689–2703.
39. Vaillant, F., Merino, D., Lee, L., Breslin, K., Pal, B., Ritchie, M.E., Smyth, G.K., Christie, M., Phillipson, L.J., Burns, C.J., et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24 (2013), 120–129.
40. Vandenberg, C.J., Cory, S., ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121 (2013), 2285–2288.
41. Vela, L., Gonzalo, O., Naval, J., Marzo, I., Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. J. Biol. Chem. 288 (2013), 4935–4946.
42. Wertz, I.E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D.J., Helgason, E., Ernst, J.A., Eby, M., Liu, J., et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471 (2011), 110–114.
43. Wilkinson, A.C., Ballabio, E., Geng, H., North, P., Tapia, M., Kerry, J., Biswas, D., Roeder, R.G., Allis, C.D., Melnick, A., et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 3 (2013), 116–127.
44. Wong, M., Tan, N., Zha, J., Peale, F.V., Yue, P., Fairbrother, W.J., Belmont, L.D., Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol. Cancer Ther. 11 (2012), 1026–1035.
45. Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I., Cleary, M.L., A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17 (2010), 198–212.